Solventum (SOLV) announced it has entered into a definitive agreement to sell its Purification & Filtration business to Thermo Fisher Scientific (TMO) for $4.1B. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4B in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SOLV:
- Thermo Fisher close to deal to buy Solventum’s filtration unit, WSJ reports
- Trian boosts stakes in Solventum, U-Haul and Wendy’s, cuts Allstate stake
- Trian says Solventum’s shares could be worth $140 by year-end 2027
- Activist Trian sends letter to Solventum holders, CNBC reports
- Trian sends letter to Solventum holders, says shares undervalued, CNBC says